Moderna (MRNA) Net Cash Flow (2018 - 2026)
Moderna (MRNA) posted quarterly Net Cash Flow of -$183.0 million for Q2 2026, up 47.11% year-over-year from -$124.4 million in Q2 2025, and up 73.44% on a QoQ basis from -$689.0 million in Q1 2026.
Moderna (MRNA) Net Cash Flow (2018 - 2026) Analysis & Trends
Moderna has reported Net Cash Flow for 9 years, with the latest figure at -$183.0 million in Q2 2026.
- Net Cash Flow for Q2 2026 came in at -$183.0 million, up 47.11% year-over-year; the trailing twelve-month figure through Jun 2026 was $443.0 million (up 136.92% YoY), and the FY2025 annual result was $666.0 million, up 166.67% from the prior year.
- Net Cash Flow advanced to -$183.0 million in Q2 2026, from -$689.0 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $1.5 billion in Q4 2025 and troughed at -$2.2 billion in Q2 2022.
- A 5-year average of -$285.4 million and a median of -$165.5 million in 2025 frame the typical range for Net Cash Flow.
- The widest annual swing landed in 2022, when Net Cash Flow slumped 1450.93%; it then jumped 1232.0% in 2024.
- A 5-year view of Net Cash Flow shows it stood at $176.0 million in 2022, then plunged by 114.2% to -$25.0 million in 2023, then jumped by 1232.0% to $283.0 million in 2024, then surged by 416.96% to $1.5 billion in 2025, then slumped by 112.51% to -$183.0 million in 2026.
- Per Business Quant data, the three most recent Net Cash Flow figures were -$183.0 million in Q2 2026, -$689.0 million in Q1 2026, and $1.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn | -183.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -183.00 Mn |
| Jun 30, 2026 | -183.00 Mn |
| Mar 31, 2026 | -689.00 Mn |
| Mar 31, 2026 | -689.00 Mn |
| Dec 31, 2025 | 1.46 Bn |
| Dec 31, 2025 | 1.46 Bn |
| Sep 30, 2025 | -148.00 Mn |
| Sep 30, 2025 | -148.00 Mn |
| Jun 30, 2025 | -346.00 Mn |
| Jun 30, 2025 | -346.00 Mn |
| Mar 31, 2025 | -303.00 Mn |
| Mar 31, 2025 | -303.00 Mn |
| Dec 31, 2024 | 283.00 Mn |
| Dec 31, 2024 | 283.00 Mn |
| Sep 30, 2024 | -834.00 Mn |
| Sep 30, 2024 | -834.00 Mn |
| Jun 30, 2024 | 409.00 Mn |
| Jun 30, 2024 | 409.00 Mn |
| Mar 31, 2024 | -857.00 Mn |
| Mar 31, 2024 | -857.00 Mn |